Quick jump to page content
  • Main Navigation
  • Main Content
  • Sidebar
  • Register
  • Login
##common.pageHeaderLogo.altText##
  • Home
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Current
  • Archives
  • Submission

Search

Advanced filters

Search Results

Daylight Photodynamic Therapy of Actinic Keratosis with BF-200 ALA compared to MAL

T Dirschka, S Ekanayake-Bohlig, R Dominicus, R Aschoff, E Herrera-Ceballos, R Botella-Estrada, A Hunfeld, B Schmitz, H Lubbert, S Puig

Page s115

Poster PDF

Photodynamic Therapy for Actinic Keratosis and Field Cancerization Using BF-200 ALA: Results of Pivotal Phase III Trials and Follow-Up

T Dirschka, U Reinhold, M Foguet, B Novak, B Schmitz, H Luebbert, R M Szeimies

Page s117

Poster PDF

Ingenol Mebutate 0.06% Gel for Field Treatment of Actinic Keratosis on 250 cm2 of Skin on Trunk and Extremities: A Randomized Dose-Finding Trial

Daniel Siegel, Emil Tanghetti, Neil Brody, Michael Freeman, Torsten Skov, Astrid Petersen, Fabrice Clonier, Lynda Spelman

Page 128-142

Full Article PDF Supplementary Material PDF

Prevention of Actinic Keratosis by a Very High UVB/UVA Daily Photoprotectant

S Seite, D Moyal

Page s118

Poster PDF

Real-World Treatment and Patient-Specific Characteristics of Actinic Keratosis in the USA

Jes B Hansen, Mads D Faurby, Meg Corliss, Steven R Feldman

Page S48

Poster PDF

Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp, or Approximately 250 cm2 on the Chest: A Phase III, Randomized, Controlled Trial

C William Hanke, Lorne Albrecht, Laerke K Kyhl, Thomas Larrson, Marie L Oesterdal, Lynda Spelman

Page S46

Poster PDF

Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial

T Dirschka, M Ulrich, U Reinhold, R Dominicus, R Aschoff, R.M. Szeimies

Page S47

Poster PDF

Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy

Justin Marson, James Del Rosso, Neal Bhatia, Darrell Rigel

Page 83-89

PDF

VDA-1102 : A Novel Well-Tolerated Treatment For Actinic Keratosis

Chaim M Brickman, Vered Behar, Galit Zelinger, Oren M Becker

Page S76

Poster PDF

Combination Therapy with Short Contact Topical Calcipotriene Foam and Fluorouracil Following Cryotherapy for Actinic Keratosis

Angela Y Moore, Madalyn Nguyen

Page S72

Poster PDF

Expedited Resolution of 5-Fluorouracil-Induced Erythema and Barrier Dysfunction with White Petrolatum

Melody Maarouf, Bryan Kromenacker, Eric Brucks, Vivian Shi

Page 279-282

Full Article PDF

Photodynamic Therapy in 2020: Lights in the Darkness

Neal Bhatia

Page 312-320

PDF

Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis

G Martin, B Berman, S Feldman, A Armstrong , M Edwards, S Graziadio, R McCool, M Arber, E Carr, D James, M Chapman-Rounds, E Fumero, M Schuchardt, A Grada

Page s81

Poster PDF

Efficacy and Safety of Ingenol Mebutate in Patients With Actinic Keratosis on Face and Scalp: Subgroup Analysis of Two Vehicle-Controlled Trials According to Age (<65 and ≥65 Years)

Hee Kim, Jes Hansen, Mads Faurby, et al.

Page 168

Poster PDF

Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Laura Padulles, Francisco Hernandez, David Cutler, Mark Lebwohl

Page s26

Poster PDF

Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light

U Reinhold, T Dirschka, R Ostendorf, R Aschoff, C Berking, W Philipp-Dormston, R.M. Szeimies

Page S49

Poster PDF

Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions

Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl

Page s25

Poster PDF

Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol

Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee

Page s19

Poster PDF

Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination

Angela Yen Moore, Stephen Moore

Page S46

Poster PDF

Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies

Andrew Blauvelt, Steven Kempers, Seth Forman, Edward Lain, Suzanne Bruce

Page s63

Poster PDF

Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis

Scott Freeman, Miriam Bettencourt, Meg Corliss, Nikeshia Dunkelly-Allen, Karen A Veverka

Page s65

Poster PDF

Auricular Distortion Following Cryotherapy

Jason Bard, Heather Kornmehl , Joesph Wentzell

Page 180-182

PDF

Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies

Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan

Page s121

Poster PDF

Efficacy of tirbanibulin ointment 1% across different patient populations: pooled results from two Phase 3 studies

Brian Berman, Adria Gual, Ayman Grada, Emilio Fumero, Laura Padulles, Francisco Hernandez

Page s27

Poster PDF

Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl

Page s120

Poster PDF
1 - 25 of 26 items 1 2 > >> 

 

 

 

 

180x77

Make a Submission

SKIN is a bi-monthly, peer-reviewed, online medical journal dedicated to providing an enhanced route to disseminate new dermatologic knowledge on all aspects of cutaneous disease. The Journal is Open Access. ISSN: 2574-1624

Important Links

  • About the Journal
  • Editorial Team
  • Submissions
  • Contact

Contact

  • Email: jofskin@gmail.com
  • Website: www.jofskin.org
  • Mailing Address: PO Box 569 Millwood NY 10546
OJS Hosting, Support, and Customization by: OpenJournalSystems.com

Modal Header